LITERATURE REVIEW OF NEPHROTIC EDEMA MANAGEMENT

Agysza Ulfiantika Pramuti[1], Prasetyaning Estu Pratiwi[1]

[1]Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jawa Timur

Corresponding Author

Agysza Ulfiantika Pramuti

Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jawa Timur

Rungkut Madya Street No. 191, Rungkut Kidul, Rungkut District, Surabaya, Jawa Timur 60293

Tel/Fax: +6285231980965

E-mail: gizapramuti@gmail.com

Abstract

Background. Nephrotic syndrome (NS) is a renal disorder characterized by proteinuria, hypoalbuminemia, hyperlipidemia, and edema. Among these, edema remains a prominent clinical manifestation affecting patient quality of life and signaling disease progression. Understanding its multifactorial pathophysiology is essential for optimizing treatment strategies.

Methods. A systematic review of peer-reviewed literature from 2020 to 2024 was conducted using PubMed, ScienceDirect, and Elsevier. Search terms included "Edema," "Nephrotic Syndrome," "Proteinuria," and "Nephrotic Edema." Relevant articles, including case reports, reviews, and clinical studies, were critically analyzed to identify advances in understanding and managing edema in NS.

Discussion. Edema in NS arises from a combination of hypoalbuminemia-induced oncotic pressure reductions, increased sodium retention, and altered vascular permeability. Standard therapies, such as diuretics and dietary sodium restriction, address these mechanisms but may be insufficient for resistant cases. Emerging strategies include combination diuretics, targeted immunomodulators, and personalized approaches based on genetic predispositions and hormonal influences. Advanced outcome measures now enable improved assessment of treatment effectiveness and patient outcomes experiences.

Conclusion. Effective management of nephrotic edema requires a holistic approach, integrating conventional therapies with emerging innovations. Advances in molecular research

and diagnostic precision are paving the way for personalized interventions, emphasizing the need for multidisciplinary care to improve outcomes and enhance patient quality of life.

Keywords: Edema, Nephrotic Syndrome, Proteinuria, Nephrotic Edema, Pathophysiology.

Introduction

Nephrotic syndrome (NS) is a renal condition characterized by proteinuria, hypoalbuminemia, hyperlipidemia, and edema, with edema being one of its most debilitating symptoms affecting the quality of life.[1] The development of edema in NS is linked to reduced oncotic pressure, increased vascular permeability, and abnormal sodium retention mediated by hormonal and renal factors.[2]

Addressing refractory edema remains a significant challenge in clinical practice. The use of combination diuretics has shown promise in managing cases resistant to conventional treatment.[2] Additionally, new therapies targeting the mechanisms of proteinuria and sodium retention offer potential alternatives for improving patient outcomes[1]. Pediatric cases often highlight the interplay between genetic predispositions and hormonal factors, which influence the severity and treatment of edema.[3]

Complications associated with NS, such as increased susceptibility to infections, add complexity to its management. Recurrent infections are commonly observed and are often worsened by the immunosuppressive effects of treatments such as corticosteroids and tacrolimus.[4] Opportunistic infections in patients undergoing these therapies underscore the importance of close monitoring and comprehensive care strategies.[5]

Advances in managing edema include the development of outcome measures to better evaluate its severity and treatment response. Such tools, alongside growing insights into genetic and molecular factors, are paving the way for more precise and personalized approaches to care. [3,4]

Methods

A systematic review of peer-reviewed articles, reports, case studies, and journals from 2020 to 2024 was conducted using databases such as PubMed, ScienceDirect, and Elsevier. Search terms included “Edema,” “Nephrotic Syndrome,” “Proteinuria,” and “Nephrotic Edema.”

Discussion

Nephrotic syndrome (NS) is a complex and multifaceted clinical condition, characterized by heavy proteinuria, hypoalbuminemia, hyperlipidemia, and edema. [2] Edema in patients with NS is one of the most bothersome symptoms and often poses a challenge in clinical management. [1] Although various approaches to treat edema have been developed, including the use of diuretics and sodium restriction, many patients develop resistance to these treatments. [5] Recent studies have shown that a combination of diuretics may be an effective strategy for treating refractory edema in patients with NS, it needed a combination approach in the management of refractory edema.[2]

Edema in nephrotic syndrome occurs due to a complex interaction between several pathophysiological mechanisms.[3] Decreased serum albumin levels cause a decrease in colloid osmotic pressure, resulting in transudation of fluid from the intravascular space to the interstitial space.[4] This is exacerbated by increased glomerular permeability to protein and sodium retention caused by activation of compensatory neurohormonal mechanisms.[5] The "underfill" hypothesis explains that urinary protein loss causes intravascular hypovolemia, triggering sodium and water retention by the kidneys in response to decreased effective blood volume. On the other hand, the "overfill" hypothesis suggests that sodium retention can occur independently of intravascular volume status, leading to increased fluid volume and edema.[2]

Pathophysiology of Edema in Nephrotic Syndrome

Edema in nephrotic syndrome (NS) primarily results from hypoalbuminemia, which reduces plasma oncotic pressure and promotes fluid accumulation in interstitial spaces. Hormonal dysregulation also plays a crucial role. One study highlighted the role of epithelial sodium channels (ENaC) in the renal tubules, where their upregulation leads to sodium retention and contributes significantly to refractory edema.[1,2] Genetic and hormonal interactions further complicate the presentation, as another study explored potential genes and hormonal influences contributing to fluid retention and proteinuria in childhood NS.[7] These findings emphasize the need for therapies targeting both systemic and renal-specific mechanisms of fluid retention.

Diuretic Resistance and Combination Therapies

One of the most challenging aspects of NS management is diuretic resistance, where conventional therapies fail to induce adequate diuresis. A case study described the effectiveness of combination diuretics, such as loop diuretics with thiazides, in managing resistant edema.[1] This synergistic approach enhances sodium excretion by targeting different segments of the

nephron. ENaC inhibitors have also shown promise as adjunct therapies for refractory edema, directly addressing the sodium retention mechanisms highlighted in the literature.[2] These strategies represent significant progress in overcoming diuretic resistance in NS.

Immunosuppressive Therapy and Associated Risks

The use of immunosuppressive therapies, such as corticosteroids and calcineurin inhibitors, is essential for managing immune-mediated NS but increases the risk of infections. Research has reported that up to 20% of adult NS patients experience recurrent infections, including urinary tract infections and pneumonia. [3] Another case highlighted a rare occurrence of nocardiosis in a patient receiving glucocorticoid and tacrolimus therapy, emphasizing the vulnerability of NS patients to opportunistic infections.[5] These findings underscore the importance of infection monitoring and prophylactic measures during treatment.[5]

Nutritional Management

Nutritional interventions are critical in the comprehensive care of NS. A low-sodium diet helps control edema and blood pressure, while protein intake must be balanced to address hypoalbuminemia without exacerbating renal damage. One study emphasized the role of individualized dietary plans to improve fluid balance and support recovery.[1] Another study discussed the management of nephrotic-range proteinuria, where optimizing nutrition plays a role in reducing complications such as chyluria.[9]

Cardiovascular Complications

Edema in NS is not limited to peripheral tissues but may involve myocardial tissues. Research highlighted the association of chronic kidney disease with myocardial edema and diffuse fibrosis, which may contribute to cardiovascular risks in NS patients.[6] This underscores the importance of monitoring cardiac health and incorporating interventions to reduce cardiovascular complications in NS management.[8]

Long-term Monitoring and Outcome Measures

The development of standardized outcome measures for assessing NS symptoms and complications is essential for clinical practice. A study developed clinician-reported outcome measures (CMRs) specifically for edema, allowing healthcare providers to track patient progress and adjust treatment plans effectively.[8] This tool ensures better monitoring and tailored care for patients with complex and refractory symptoms.

Rare Presentations and Case Studies

Rare presentations of NS provide unique insights into the condition’s complexity. Research discussed cases of NS without nephrotic-range proteinuria, which require a different

diagnostic and therapeutic approach.[4] Another study described a rare case of NS associated with Tangier disease, emphasizing the need for individualized care plans in atypical scenarios.[10] Similarly, neonatal NS cases highlighted the importance of early diagnosis and management to improve outcomes.[11]

Future Directions and Research Gaps

Recent advancements in understanding NS pathophysiology have paved the way for novel therapeutic approaches. Studies proposed the integration of ENaC inhibitors and immunomodulators into treatment regimens to target refractory edema and immune dysregulation simultaneously.[2] Research into genetic and hormonal factors offers opportunities for personalized medicine in NS management.[7] Further studies are needed to evaluate the long-term efficacy and safety of emerging therapies and explore the role of cardiovascular and metabolic factors in NS progression.[3]

Conclusion

The management of nephrotic syndrome is a multifaceted challenge requiring a combination of pharmacological, nutritional, and supportive strategies. Addressing diuretic resistance, minimizing infection risks, and considering the long-term complications of NS are crucial to improving patient outcomes. Innovations in therapeutic approaches, such as combination diuretics, ENaC inhibitors, and immunomodulators, alongside standardized clinical tools, provide hope for more effective management. However, continuous research into NS's underlying mechanisms and individualized approaches remains essential.

References

1. Fratila VG, Lupusoru G, Sorohan BM, Obrisca B, Mocanu V, Lupusoru M, et al. Combination of diuretics in states of resistant nephrotic edema: a case presentation. Maedica. 2024;19(3):641–7. https://doi.org/10.26574/maedica.2024.19.3.641
2. Frățilă VG, Lupușoru G, Sorohan BM, Obrișcă B, Mocanu V, Lupușoru M, et al. Nephrotic syndrome: from pathophysiology to novel therapeutic approaches. Biomedicines. 2024;12(3):569. https://doi.org/10.3390/biomedicines12030569
3. Shahraki Ghadimi Z, Sadeghi Bojd S, Parvane N, Atabaki M, Alijani E. Nephrotic syndrome and recurrent infection. Iran J Allergy Asthma Immunol. 2024;23(5):594–9. https://doi.org/10.18502/ijaai.v23i5.16754

4. Sheikh JA, Syed U, Osama SM. Nephrotic syndrome without nephrotic range proteinuria. Cureus. 2024;16(7):e64342. https://doi.org/10.7759/cureus.64342
5. Taguchi K, Mitsuishi Y, Kimura K, Ito S, Fukami K. Nocardiosis in a patient with nephrotic syndrome treated with glucocorticoids and tacrolimus. Intern Med. 2024. https://doi.org/10.2169/internalmedicine.4301-24
6. Arcari L, Engel J, Freiwald T, Zhou H, Zainal H, Gawor M, et al. Cardiac biomarkers in chronic kidney disease are independently associated with myocardial edema and diffuse fibrosis by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2021;23(1):71. https://doi.org/10.1186/s12968-021-00762-z
7. El-Halaby H, Bakr A, Eid R, Abdalla HA, Hamdy N, Shamekh N, et al. Edema in childhood nephrotic syndrome: possible genes-hormones interplay. J Genet Eng Biotechnol. 2022;20(1):30. https://doi.org/10.1186/s43141-022-00310-x
8. Gipson DS, Pal M, Desmond H, Anderson C, Walsh L, Trachtman H, et al. Developing an edema clinician-reported outcome measure for nephrotic syndrome. Glomerular Dis. 2023;3(1):132–9. https://doi.org/10.1159/000531505
9. Kaur A, Kandari S, Saini S, Dhoot DK, Kandari A. Chyluria associated with nephrotic-range proteinuria. Cureus. 2022;14(7):e26690. https://doi.org/10.7759/cureus.26690
10. Gama R, Murphy E, Salisbury J, Kassam S, Simmonds N, Roufosse C, et al. A rare case of nephrotic syndrome and Tangier disease. CEN Case Rep. 2023;12(3):265–9. https://doi.org/10.1007/s13730-022-00761-8
11. Chetan C, Singh SK, Patra S, Gupta G. Neonatal nephrotic syndrome: all is not gloomy. BMJ Case Rep. 2024;17(1):e255584. https://doi.org/10.1136/bcr-2023-255584